Business Standard

Bharat Biotech's Covaxin effective against Delta plus variant, says study

The study released on Monday showed that Covaxin provides 65.2 per cent protection against the Delta variant which was first detected in India

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Premium

The study published as a pre-print on bioRxiv said that Sera of vaccines among Covid naïve recovered cases with full vaccination and breakthrough cases demonstrated 1.3, 2.5 and 1.9-fold reduction against Delta variant in comparison to B.1 variant respectively.

Ruchika Chitravanshi New Delhi
Bharat Biotech's Covaxin is effective against the Delta and Delta plus variant, a study by the Indian Council of Medical Research and National Institute of Virology has said.
 
The study released on Monday showed that Covaxin provides 65.2 per cent protection against the Delta variant which was first detected in India. The Delta variant which has spread to 99 countries is a variant of concern and was also responsible for the second wave in India.
 
The Delta variant has also been identified as the leading cause of breakthrough infections globally among vaccinated individuals, the study said. The study

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in